Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/117865
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial |
Author: | Costello, S.P. Hughes, P.A. Waters, O. Bryant, R.V. Vincent, A.D. Blatchford, P. Katsikeros, R. Makanyanga, J. Campaniello, M.A. Mavrangelos, C. Rosewarne, C.P. Bickley, C. Peters, C. Schoeman, M.N. Conlon, M.A. Roberts-Thomson, I.C. Andrews, J.M. |
Citation: | JAMA: Journal of the American Medical Association, 2019; 321(2):156-164 |
Publisher: | American Medical Association |
Issue Date: | 2019 |
ISSN: | 0098-7484 1538-3598 |
Statement of Responsibility: | Jane M. Andrews … Robert V. (Rob) Bryant … Samuel P. Costello … Patrick A. Hughes … Ian C. Roberts-Thomson … Andrew D. Vincent … et al. |
Abstract: | Importance: High-intensity, aerobically prepared fecal microbiota transplantation (FMT) has demonstrated efficacy in treating active ulcerative colitis (UC). FMT protocols involving anaerobic stool processing methods may enhance microbial viability and allow efficacy with a lower treatment intensity. Objective: To assess the efficacy of a short duration of FMT therapy to induce remission in UC using anaerobically prepared stool. Design, Setting, and Participants: A total of 73 adults with mild to moderately active UC were enrolled in a multicenter, randomized, double-blind clinical trial in 3 Australian tertiary referral centers between June 2013 and June 2016, with 12-month follow-up until June 2017. Interventions: Patients were randomized to receive either anaerobically prepared pooled donor FMT (n = 38) or autologous FMT (n = 35) via colonoscopy followed by 2 enemas over 7 days. Open-label therapy was offered to autologous FMT participants at 8 weeks and they were followed up for 12 months. Main Outcomes and Measures: The primary outcome was steroid-free remission of UC, defined as a total Mayo score of ≤2 with an endoscopic Mayo score of 1 or less at week 8. Total Mayo score ranges from 0 to 12 (0 = no disease and 12 = most severe disease). Steroid-free remission of UC was reassessed at 12 months. Secondary clinical outcomes included adverse events. Results: Among 73 patients who were randomized (mean age, 39 years; women, 33 [45%]), 69 (95%) completed the trial. The primary outcome was achieved in 12 of the 38 participants (32%) receiving pooled donor FMT compared with 3 of the 35 (9%) receiving autologous FMT (difference, 23% [95% CI, 4%-42%]; odds ratio, 5.0 [95% CI, 1.2-20.1]; P = .03). Five of the 12 participants (42%) who achieved the primary end point at week 8 following donor FMT maintained remission at 12 months. There were 3 serious adverse events in the donor FMT group and 2 in the autologous FMT group. Conclusions and Relevance: In this preliminary study of adults with mild to moderate UC, 1-week treatment with anaerobically prepared donor FMT compared with autologous FMT resulted in a higher likelihood of remission at 8 weeks. Further research is needed to assess longer-term maintenance of remission and safety. Trial Registration: anzctr.org.au Identifier: ACTRN12613000236796. |
Keywords: | Humans Colitis, Ulcerative Colonoscopy Enema Remission Induction Transplantation, Autologous Transplantation, Homologous Double-Blind Method Anaerobiosis Adult Middle Aged Female Male Metabolome Young Adult Surveys and Questionnaires Gastrointestinal Microbiome Fecal Microbiota Transplantation |
Rights: | © 2019 American Medical Association. All rights reserved. |
DOI: | 10.1001/jama.2018.20046 |
Grant ID: | NHMRC |
Published version: | http://dx.doi.org/10.1001/jama.2018.20046 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.